Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
Tuesday, 17 June 2025 ()
Weight Loss drug maker Eli Lilly And Co (NYSE:LLY) has agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Verve’s lead program (VERVE-102) is a potential first-in-class in vivo gene editing…
|
||||
You Might Like |
||||
